[Detection of human anti-mouse antibody in patients receiving 111In-antimyosin Fab: multicenter clinical study in Japan].
In the multicenter clinical study of 111In-Antimyosin Fab (74 MBq, 0.5 mg), human anti-mouse antibody (HAMA) titers have been evaluated in serum from 456 patients using the sensitive enzyme-linked immunosorbent assay. Presence of HAMA was confirmed by the neutralization test or using the size exclusion high performance liquid chromatography (HPLC) analysis in 11 of 393 patients (2.8%). HAMA was still detectable in 2 patients even 40 weeks after injection. None of 7 patients judged as positive for the intradermal test, a patient with vascular pain or 3 patients with fever or flare and itching with fever, developed detectable levels HAMA in their serum. These results suggest that patients may develop HAMA response after infusion of 111In-Antimyosin Fab, but pathogenic role of HAMA in these patients remains to be studied.
Kawai
C
C
Department of Internal Medicine, Kyoto University Hospital, Japan.
Endo
K
K
Matsumori
A
A
Nishimura
T
T
Hosono
M
M
D000818:Animals; D000910:Antibodies, Heterophile / Q000096:biosynthesis*; D000911:Antibodies, Monoclonal / Q000276:immunology; D004797:Enzyme-Linked Immunosorbent Assay; D006321:Heart / Q000000981:diagnostic imaging*; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000276:immunology*; D007205:Indium Radioisotopes; D051379:Mice / Q000276:immunology*; D015337:Multicenter Studies as Topic; D009218:Myosins / Q000276:immunology; D011877:Radionuclide Imaging
D000910:Antibodies, Heterophile; D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D007205:Indium Radioisotopes; D009218:Myosins